President Trump has signed an executive order as part of an effort to end the practice of voting by mail in the U.S., though election law scholars say he doesn't have the authority. (Image credit: Godofredo A. Vásquez)
President Trump has signed an executive order as part of an effort to end the practice of voting by mail in the U.S., though election law scholars say he doesn't have the authority. (Image credit: Godofredo A. Vásquez)
(RTTNews) - PVH Corp. (PVH) on Tuesday reported a fourth-quarter net loss of $158.3 million or $3.46 per share, compared to net income of $157.2 million or $2.83 per share last year.
(RTTNews) - PVH Corp. (PVH) on Tuesday reported a fourth-quarter net loss of $158.3 million or $3.46 per share, compared to net income of $157.2 million or $2.83 per share last year.
Anti-vaccine Health Secretary Robert F. Kennedy Jr.—who has long dismissed reams of data on lifesaving vaccines as being insufficient to prove safety—is pushing the Food and Drug Administration to lift restrictions on over a dozen injectable peptide treatments. The treatments have little to no efficacy data behind them and were previously banned by the FDA for posing significant safety risks. Kenn...
Anti-vaccine Health Secretary Robert F. Kennedy Jr.—who has long dismissed reams of data on lifesaving vaccines as being insufficient to prove safety—is pushing the Food and Drug Administration to lift restrictions on over a dozen injectable peptide treatments. The treatments have little to no efficacy data behind them and were previously banned by the FDA for posing significant safety risks. Kennedy is a self-proclaimed "big fan" of the risky treatments. Peptides, generally, are chains of amino acids linked together with peptide bonds, a link between the carboxyl group of one amino acid and the amino group of another. Bioactive peptides can have a range of cellular functions and influence various biochemical processes. Well-established, FDA-approved types of peptide drugs include GLP-1s for obesity and insulin for diabetes. But online, peptide drugs are now seemingly synonymous with unproven, non-FDA-approved treatment. They've grown extremely popular among wellness influencers, celebrities, and "biohackers," who claim without evidence that peptides can treat various diseases, reverse aging, and improve appearance. On February 27, Kennedy touted such unproven peptides as a guest on Joe Rogan's podcast, saying he had used them to treat injuries with "really good effect." He also vowed to end the FDA's "war on peptides" and revealed his plan to reverse the FDA's restrictions on many of them. Read full article Comments
Company said it achieved valuation of $852bn, mentioning in a blog post it generates $2bn a month in revenue OpenAI announced on Tuesday it had closed a fundraising round of $122bn and achieved a valuation of $852bn. The funding cements the ChatGPT maker as one of the most highly valued private companies in the world. The artificial intelligence firm received multibillion-dollar investments from c...
Company said it achieved valuation of $852bn, mentioning in a blog post it generates $2bn a month in revenue OpenAI announced on Tuesday it had closed a fundraising round of $122bn and achieved a valuation of $852bn. The funding cements the ChatGPT maker as one of the most highly valued private companies in the world. The artificial intelligence firm received multibillion-dollar investments from companies including Amazon, Nvidia and SoftBank, which committed $110bn, according to the Wall Street Journal . OpenAI also allowed a select group of individual investors to contribute around $3bn. The funding round ranks among the highest-ever in Silicon Valley. Continue reading...
Bloom Productions/DigitalVision via Getty Images My, how time seems to fly! It seemed like not long ago that I last wrote an article about WesBanco, Inc. ( WSBC ). But looking back, the last piece that I published about it came out in August of 2024. At that time, news had just broken that WesBanco and Premier Financial were going to merge in an all-stock deal that valued the latter at $959 millio...
Bloom Productions/DigitalVision via Getty Images My, how time seems to fly! It seemed like not long ago that I last wrote an article about WesBanco, Inc. ( WSBC ). But looking back, the last piece that I published about it came out in August of 2024. At that time, news had just broken that WesBanco and Premier Financial were going to merge in an all-stock deal that valued the latter at $959 million. At that time, I viewed this transaction in a favorable light. Leading up to that point, WesBanco had faced certain financial challenges, though there had been some signs of improvement. I viewed the transaction as appealing based on valuation matters and the prospect that there would be the opportunity for synergies of about $41.4 million. Fast forward to today, and the most recent data available does show some nice results for WesBanco. However, asset quality for the company is mixed, and the stock price is rather lofty in relation to earnings. This creates more of a mixed bag than what we saw back then. My overall assessment is that, on the whole, WesBanco is not a bad prospect. But I do think that there are certainly better opportunities out there today. Because of this, I believe that downgrading WesBanco from a Buy to a Hold makes sense here. I'm No Longer Banking On WesBanco Author - SEC EDGAR Data If you were to analyze WesBanco based only on its fundamentals and not on what caused their change, you would think that the business is growing rapidly on an organic basis. In the chart above, for instance, you can see certain changes to its balance sheet over the last three years. Back in 2023, the company had deposits of $13.17 billion. But those have since ballooned to $21.67 billion as of the end of 2025. This was overwhelmingly thanks to the company's merger with Premier Financial, which brought in $7.9 billion of assets that included $5.9 billion of loans and $1.2 billion of investment securities. Naturally, deposits would have been significant as part of this tra...
Ellen Wald, president of Transversal Consulting and senior fellow at the Atlantic Council, said that despite high oil prices she feels the price of brent should be even higher to reflect the reality of the situation amid the war with Iran. Wald said that the US could better insulate itself from the impacts of future energy crises by improving the interdependence between the US, Canada and Mexico i...
Ellen Wald, president of Transversal Consulting and senior fellow at the Atlantic Council, said that despite high oil prices she feels the price of brent should be even higher to reflect the reality of the situation amid the war with Iran. Wald said that the US could better insulate itself from the impacts of future energy crises by improving the interdependence between the US, Canada and Mexico in North American oil production. (Source: Bloomberg)
Vertex Pharmaceuticals ( VRTX ) has completed its rolling BLA submission to the US FDA for povetacicept for immunoglobulin A nephropathy (IgAN). The company used a priority review voucher with the application and is expecting an FDA review to finish within six months of the BLA's acceptance. Povetacicept is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation-inducin...
Vertex Pharmaceuticals ( VRTX ) has completed its rolling BLA submission to the US FDA for povetacicept for immunoglobulin A nephropathy (IgAN). The company used a priority review voucher with the application and is expecting an FDA review to finish within six months of the BLA's acceptance. Povetacicept is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand) cytokines, which are both involved in the pathogenesis of several autoimmune diseases. More on Vertex Pharmaceuticals Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 Transcript Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take Vertex Pharmaceuticals climbs on positive interim data from IgAN phase 3 trial Key deals this week: KORE, TopBuild, Equinix, PayPal and more